Session

Back to Programme Overview

Experimental approaches in personalised medicine in urothelium tumours

Poster Session 39

  • Location:
    Room Madrid, North Hall (Level 1)
  • Chairs:
     F. Deho, Milan (IT)
     M. Knowles, Leeds (GB)
     M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)
  • Aims and objectives of this session

    The course of bladder cancer could be affected by many factors. In order to predict the course of the disease, it is important to analyze multiple parameters. Studies presented in this session will focus also on exosomes and miRNA.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 519
Tumor-associated exosomes of urothelial bladder cancer cells affect tumor-promoting processes in normal bladder fibroblasts and support tumorigenesis

By: Baumgart S.1, Heinzelmann J.1, Krause E.2, Stöckle M.1, Stampe Ostenfeld M.3, Junker K.1

Institutes: 1Saarland University Medical Center, Dept. of Urology, Homburg, Germany, 2Saarland University Medical Center, Dept. of Physiology, Homburg, Germany, 3University Hospital Aarhus, Dept. of Molecular Medicine, Aarhus, Denmark

520
Cancer-associated fibroblasts secreted exosomal miR-146a promotes bladder cancer progression

By: Zhuang J.1, Shen L.2, Yan J.2, Guo H.1

Institutes: 1Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, 2MOE Key Laboratory of Model Animals For Disease Study, Model Animal Research Center, Dept. of Tumor Biology, Nanjing, China

521
Genomic landscape of upper urinary tract urothelial carcinoma

By: Fujii Y.1, Sato Y.1, Suzuki H.2, Shiozawa Y.2, Yoshizato T.2, Yoshida K.2, Shiraishi Y.3, Nakagawa T.1, Kume H.1, Nishimatsu H.4, Okaneya T.5, Sanada M.6, Makishima H.2, Miyano S.3, Ogawa S.2, Homma Y.1

Institutes: 1The University Of Tokyo Hospital, Dept. of Urology, Bunkyo, Japan, 2Graduate School of Medicine Kyoto University, Dept. of Pathology and Tumor Biology, Kyoto, Japan, 3Institute of Medical Science The University of Tokyo, Laboratory of DNA Information Analysis, Human Genome Center, Minato, Japan, 4The Fraternity Memorial Hospital, Dept. of Urology, Sumida, Japan, 5Toranomon Hospital, Dept. of Urology, Minato, Japan, 6Nagoya Medical Center, Advanced Diagnosis, Clinical Reserach Center, Nagoya, Japan

* 522
Molecular subtype classification of advanced bladder cancer and matched lymph-node metastases by integrative immunohistochemistry, gene expression, and mutation analyses

By: Sjödahl G.1, Eriksson P.2, Lövgren K.2, Liedberg F.1, Höglund M.2

Institutes: 1Translational Medicine, Dept. of Urologic Research, Lund, Sweden, 2Clinical Sciences, Dept. of Oncology and Pathology, Lund, Sweden

523
Withdrawn

By:

Institutes:

524
Urine based DNA methylation biomarkers for monitoring bladder cancer

By: Van Der Heijden A.2, Mengual L.1, Ingelmo-Torres M.1, Lozano J.3, Van Rijt-Van De Westerlo C.4, Santos P.1, Geavlete B.5, Moldoveanu C.5, Ene C.5, Dinney C.6, Czerniak B.7, Schalken J.4, Kiemeney L.8, Ribal M.1, Witjes J.2, Alcaraz A.1

Institutes: 1Hospital Clinic, IDIBAPS, Dept. of Urology, Barcelona, Spain, 2Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 3Hospital Clinic, CIBERehd, IDIBAPS, Barcelona, Spain, 4Radboudumc, Dept. of Experimental Urology, Nijmegen, The Netherlands, 5Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania, 6MD Anderson Cancer Center, Dept. of Urology, Houston, Texas, United States of America, 7MD Anderson Cancer Center, Dept. of Pathology, Houston, Texas, United States of America, 8Radboudumc, Dept. of Health Evidence, Nijmegen, The Netherlands

525
Utilization of next-generation sequencing techniques to investigate markers for chemosensitivity in bladder cancer patients treated with neoadjuvant chemotherapy prior to radical cystectomy

By: Boström P.1, Fey V.2, Kaikkonen E.3, Lamminen T.1, Laitinen A.1, Mirtti T.4, Koskinen I.5, Salminen A.1, Taimen P.6, Schleutker J.3

Institutes: 1Turku University Hospital, Dept. of Urology, Turku, Finland, 2University of Turku, Institution of Biotechnology, Turku, Finland, 3Turku University, Dept. of Medical Biochemistry and Genetics, Turku, Finland, 4Helsinki University Hospital and Finnish Institute For Molecular Medicine, University of Helsinki, Dept. of Pathology (HUSLAB), Helsinki, Finland, 5Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 6Turku University Hospital, Dept. of Pathology, Turku, Finland

526
Bladder cancer-secreted extracellular vesicles destroy vascular endothelial barriers

By: Yoneyama M.S.1, Hatakeyama S.2, Funyu T.3, Tsuboi S.1, Ohyama C.2

Institutes: 1Oyokyo Kidney Research Institute, Dept. of Cancer Immunology and Cell Biology, Hirosaki, Japan, 2Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 3Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan

527
KRT5 and KRT20 expression predicts recurrence and progression of stage pT1 non-muscle-invasive bladder cancer (NMIBC)

By: Breyer J.1, Wirtz R.2, Denzinger S.1, Erben P.3, Kriegmair M.3, Stoehr R.4, Eckstein M.4, Burger M.1, Otto W.1, Hartmann A.4

Institutes: 1University of Regensburg, Dept. of Urology, Regensburg, Germany, 2Stratifyer Molecular Pathology GmbH, Cologne, Germany, 3University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, 4University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany

528
Cell-free DNA from urine samples – a valuable source for bladder cancer biomarkers?

By: Salomo K., Moritz S., Füssel S., Wirth M.

Institutes: Universitätsklinikum Carl Gustav Carus, Dept. of Urology, Dresden Johannstadt Nord, Germany

529
SMYD3 drives IGF-1R-AKT pathway activation in bladder cancer

By: Liu L.1, Fan Y.2, Wang K.2, Yan K.2, Liu C.2

Institutes: 1Shandong University, School of Nursing, Jinan, China, 2Shandong University Qilu Hospital, Dept. of Urology, Jinan, China

530
Her2 alterations in muscle-invasive bladder cancer: There is more than protein expression in patient selection for targeted therapy

By: Kiss B.2, Wyatt A.3, Douglas J.4, Skuginna V.2, Mo F.3, Anderson S.3, Rotzer D.2, Fleischmann A.5, Genitsch V.5, Hayashi T.6, Neuenschwander M.5, Bürki C.7, Davicioni E.7, Collins C.3, Thalmann G.2, Black P.3, Seiler R.1

Institutes: 1Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, 2University of Bern, Dept. of Urology, Bern, Switzerland, 3University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 4University Hospital of Southampton, Dept. of Urology, Hampshire, United Kingdom, 5University of Bern, Institute of Pathology, Bern, Switzerland, 6Hiroshima University, Dept. of Urology, Hiroshima, Japan, 7GenomeDx, Biosciences, Vancouver, Canada

Molecular subtypes urothelial cancer
 M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)